Premium
Non–lung cancer specific mortality after lobectomy or sublobectomy in patients with stage IA non–small cell lung cancer ≤2 cm: A propensity score analysis
Author(s) -
Yin Jiacheng,
Zhao Mengnan,
Lu Tao,
Huang Yiwei,
Sui Qihai,
Xi Junjie,
Lin Zongwu,
Xu Songtao,
Wang Qun,
Zhan Cheng
Publication year - 2019
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25724
Subject(s) - medicine , lung cancer , propensity score matching , hazard ratio , population , copd , oncology , pneumonectomy , mortality rate , cancer , surgery , confidence interval , environmental health
Background and Objectives To investigate non‐lung cancer specific mortality between stage IA non–small cell lung cancer (NSCLC) tumors less than and equal to 2 cm treated with lobectomy and sublobectomy. Methods Surveillance, epidemiology, and end results database was queried for patients who underwent lobectomy and sublobectomy. Propensity score matching (PSM) was used to achieve balance in clinicopathological characteristics. We used Fine‐and‐Gray hazard functions to analyze cause‐specific mortality and risk factors. Standardized mortality ratios were calculated to describe cause specific mortality relative to the general population. Results After PSM, 3,844 patients underwent lobectomy and 1,922 patients underwent sublobectomy. Three leading causes of non–lung cancer mortality were cardiovascular disease (CVD), chronic obstructive pulmonary diseases (COPD), and other cancers. The 5‐year cumulative non‐lung cancer mortality of lobectomy and sublobectomy groups were 11.4% and 14.0%, respectively ( P = .090). Multivariate analyses revealed that age, sex, histology, tumor size, and marital status ( P < .01) were independent predictors of non–lung cancer specific mortality. In both groups, risks of CVD specific mortality were comparable to that in the general population, whereas the risk of COPD specific mortality was higher relative to the general population. Conclusions As a significant competing event, non–lung cancer specific mortality is comparable between stage IA NSCLC tumors less than equal to 2 cm treated with lobectomy and sublobectomy.